Studies have shown that seribantumab, a monoclonal antibody targeting the ligand binding domain of ErbB3, inhibits ErbB3 signaling and tumor growth when a HRG1 autocrine loop is present52,61. This evidence concerns the gene NRG1 and neoplasm.